Olestra vs Sodium Aluminum Phosphate: which is worse?

What is Olestra?

Olestra (brand name Olean) is a synthetic fat substitute made from sucrose and fatty acids. Unlike regular fats, olestra is not absorbed by the digestive system — it passes through the body unchanged, providing zero calories while mimicking fat's texture and taste in food. It was developed by Procter & Gamble and FDA-approved in 1996.

What is Sodium Aluminum Phosphate?

Sodium aluminum phosphate (SALP) is a leavening acid and food additive used in baked goods, particularly self-rising flour and baking powder. It provides a slow, sustained leavening action during baking. SALP is also used as an emulsifying salt in processed cheese products.

Documented risks

Olestra: Olestra caused significant gastrointestinal side effects that were prominently noted on mandatory warning labels: 'This Product Contains Olestra. Olestra may cause abdominal cramping and loose stools. Olestra inhibits the absorption of some vitamins and other nutrients. Vitamins A, D, E, and K have been added.' Reported gastrointestinal effects included diarrhea, abdominal cramping, oily anal leakage ('anal leakage' or 'rectal leakage'), and fatty stools. These effects were often embarrassing and uncomfortable. Multiple consumer complaints documented GI distress from Olean chips. Beyond GI effects, olestra significantly inhibits the absorption of fat-soluble vitamins (A, D, E, K) and fat-soluble carotenoids (lycopene, lutein, beta-carotene). Since fat-soluble vitamins require fat for absorption, and olestra passes through without being absorbed, it 'captures' these vitamins and carries them out of the body. Studies found olestra consumption reduced serum carotenoid levels, prompting Frito-Lay to fortify olestra products with fat-soluble vitamins to compensate. The FDA removed the mandatory GI warning requirement in 2003 after Frito-Lay argued the warning was overstated, though olestra's use had already declined dramatically due to consumer avoidance.

Sodium Aluminum Phosphate: The primary health concern with SALP is aluminum exposure. Dietary aluminum intake has been studied in relation to neurotoxicity, and there is ongoing scientific debate about whether chronic dietary aluminum exposure contributes to Alzheimer's disease risk. EFSA's 2008 review of dietary aluminum exposure concluded that the tolerable weekly intake (TWI) was being exceeded by some European populations based on total dietary aluminum sources, raising concern. A 2011 EFSA risk assessment noted that certain high-aluminum sources (including baked goods from SALP-containing leavening agents) contributed meaningfully to total dietary aluminum. The WHO has set a PTWI (provisional tolerable weekly intake) of 2 mg/kg body weight/week for total aluminum. However, the causal link between dietary aluminum from food-grade SALP and Alzheimer's disease has not been definitively established in human studies.